Jefferies initiated coverage on ACADIA Pharmaceuticals ACAD with a Buy rating and a $13.00 price target.
Jefferies analyst Thomas Wei noted, "Acadia Pharmaceuticals is developing its lead drug pimavanserin for Parkinson's disease psychosis (PDP), an indication that has no FDA-approved treatment. Having recently reported positive Phase 3 data, we believe ACAD will be able to replicate the favorable efficacy data in a confirmatory pivotal trial in 2H14 and launch pimavanserin in 2016. We see pimavanserin as a highly attractive licensing/acquisition target for pharma companies."
ACADIA Pharmaceuticals closed at $6.26 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in